At AdvantiGen Biosciences, we enable medical device development and drug discovery that improve the human condition through the creation of innovative detection reagents and technologies. This is achieved by utilizing our three core technologies to generate key biological tools.
Our first core technology is comprised of our suite of optical imaging products, which allow the tracking of proteins and cells in vitro and in vivo using the Infrared (IR) region of the spectrum. Specifically, we have licensed six fluorophores, which one of our founders developed, from the University of Wisconsin-Madison. Advantages of our fluorophores include, that they utilize IR wavelengths so there is low background signal, they are compatible with existing commercial devices, they can either be conjugated or co-translationally fused to target proteins, they can be expressed in vivo, and they work in both anaerobic and aerobic environments. These properties of AdvantiGen’s our fluorophores result in improved research and diagnostic imaging. Importantly, we are still expanding our intellectual property around this technology by additional engineering of our fluorophores to have even better properties and performance.
Our second technology is a proprietary and patented hybridoma antibody platform technology developed by members of the AdvantiGen team. This technology allows our team to produce significantly more antigen specific clones than standard fusion procedures. It also has the ability to generate both mouse and human antibodies. When utilized in combination with our fluorphore technology, this platform technology should allow AdvantiGen to develop important diagnostic and therapeutic antibodies.
Our third core technology involves our partnership with a novel monobody (antibody-like proteins) technology company to develop, in combination with our suite of fluorophores, high value reagents for use either in assays and/or as human therapeutics. Our partner’s technology not only allows AdvantiGen to develop IR fluorescent reagents to targets that are difficult to obtain traditional antibodies against, but it also allows us to develop pairs of monobodies that recognize non-overlapping epitopes on the same target and thus can be utilized together in the same assay.
By utilizing combinations of our core technologies AdvantiGen is able to provide our customers tools and services that meet or exceed their specifications leading to the acceleration of their research and development.